Archive: August, 2015

 

 

Adherium digital health lists on ASX at 10% premium

Adherium is a digital health company dedicated to developing technologies that address suboptimal medication use and remote patient management in chronic disease. 

Read more about Adherium digital health lists on ASX at 10% premium

AmpliPhi Biosciences Announces Approval of Common Stock Listing on NYSE MKT

AmpliPhi Biosciences Corporation (OTCQB: APHBD), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its shares of common stock have been approved for listing on the NYSE MKT, subject to continued satisfaction of listing requirements. 

Read more about AmpliPhi Biosciences Announces Approval of Common Stock Listing on NYSE MKT

Adherium $35m ASX IPO to expand sales of digital health technology to improve medication adherence

Australians and New Zealanders have an opportunity to invest in a highly promising digital health technology company that substantially improves medication adherence and patient health outcomes with the imminent Australian Securities Exchange (ASX) listing of Adherium Limited.

Read more about Adherium $35m ASX IPO to expand sales of digital health technology to improve medication adherence

Adherium & AstraZeneca Partner to Improve the Lives of Individuals with Respiratory Disease

New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader AstraZeneca in what the company believes is a world-first commercial arrangement combining digital health technology with blockbuster inhaler medications to improve health outcomes for patients with respiratory conditions.

Read more about Adherium & AstraZeneca Partner to Improve the Lives of Individuals with Respiratory Disease

AmpliPhi BioSciences Cleared to Submit Listing Application to NYSE MKT

AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that its board of directors has approved a one-for-fifty reverse split of the company’s common stock to become effective at market open on August 07, 2015.

Read more about AmpliPhi BioSciences Cleared to Submit Listing Application to NYSE MKT

Avita Medical Announces Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year 2015

20 July 2015 – Link here.

Read more about Avita Medical Announces Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year 2015

Sea Dragon – Market Update

SeaDragon Limited (NZX:SEA) today releases an update to the market detailing the company’s progress towards completing the Omega-3 production plant. The update also includes an overview of...

Read more about Sea Dragon – Market Update

Avita Medical Shareholder Update

22 July 2015 – link here.

Read more about Avita Medical Shareholder Update

Rex Bionics plc – Announcement of partnership agreement with MAAB

Rex Bionics Plc (AIM: RXB), the pioneer of the REX Robot technology that enhances the mobility of wheel-chair users, is pleased to announce that it has today signed a new agreement for a partnership in China with MAAB Group, an investment and trading company that specialises in sourcing and introducing innovative medical technologies into China.

Read more about Rex Bionics plc – Announcement of partnership agreement with MAAB

Avita’s ReCell featured in US Army Technology Magazine

20 July 2015. Link here.

Read more about Avita’s ReCell featured in US Army Technology Magazine

1 2